4.1 Article

Introducing the COPD Foundation Guide for Diagnosis and Management of COPD, Recommendations of the COPD Foundation

期刊

出版社

TAYLOR & FRANCIS INC
DOI: 10.3109/15412555.2013.801309

关键词

COPD; spirometry; diagnosis; treatment

资金

  1. GlaxoSmithKline plc
  2. Novartis Pharmaceuticals
  3. Pfizer Inc.
  4. Boehringer-Ingelheim
  5. AstraZeneca PLC
  6. Forest Laboratories Inc.
  7. Merck
  8. Creative Educational Concepts
  9. AstraZeneca
  10. Biomarck
  11. Centocor
  12. Mpex
  13. Nabi
  14. Novartis
  15. Otsuka

向作者/读者索取更多资源

The increasing number of treatment options for managing patients with chronic obstructive pulmonary disease (COPD) promises to improve the outcomes for COPD patients. However, determining which treatments are appropriate for individual patients has become increasingly complex. The COPD Foundation Guide for Diagnosis and Management of COPD was developed to be a practical, easy to use tool for clinicians. The Guide includes specific recommendations for diagnostic studies and treatments based on specific diagnostic criteria. This manuscript describes the rationale for the development of the Guide, the process used, the rationale for the specific recommendations and the plans for further development. The current recommendations of the COPD Foundation have been summarized in the form of Pocket Cards, which may be obtained from the Foundation at no charge (1-866-316-COPD (2673), www.copdfoundation.org).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据